FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesCOVID-19 and the Clinical Supply Chain: Mitigating Risk and Maintaining Business Continuity
Topics: COVID-19, Pharma Industry, Supply Chain
Position Paper
Free
4G Clinical webinar - Mitigating Clinical Supply Chain Risk as the Pandemic Continues
Topics: COVID-19, Project Management, Supply Chain
Webinar
Free
2023 US Conference - Sponsorship and Exhibitor Overview
Topic: Conference
Video
Free
